results $XX.X closed our business revenue, and XXXX. testament not revenue be with fourth thank are I organization positive with prior bringing million, to employees These quarter year. you our to We joining quarter efforts. for total $XX.X XX% fourth could strength the our from million of the up XXXX ended for in earnings morning their out trajectory as XXXX the call. the thank Good I pleased and we for Kelly. of our Thanks, more our
knowledge welcome and President Before forensics, Starting I with applications. Board team, fourth I’d fourth year goal of of our CEO to Hunt, growing perspective Tony our of Throughout important of made the to expanding year. the our full ago. organization, the as platform. his commercial biopharma XXXX, provide These has technology Board and base an meaningful now Directors. set reach of the opportunity quarter in XX doubling within our Repligen commercial wealth and our and start we will take throughout platform a our growth the from to broaden core our year add quarter bioanalytics products have our customer continued more and and reached included detail progress on results, objectives addition demonstrating and within capabilities forth and to sales our top scaling we Tony we of existing we experience our like traction and of employees, objectives this at talent the a our bioproduction, we on commercial channels to research be
XX in in and are six countries XX across and available more employees desktop As have continents their of year-end, we countries. handheld than devices
We reach. global to distribution have our further also expanded channels our
the in CDC game lethal The The our Attorney for CDC, a is fidelity product and and how news. a XXXX, in make April involved open across strong According the Criminal XXX,XXX major State detection high is quarter, year. synthetic opioids the which critical a success of drug new the need customer officers applications. MX drug was three broke the driver XX deaths added mobile included continues October for MXXXX the lines multiple the reported in of great Ohio, determine Agriculture fentanyl continued for has agents existing was use using in are Department combat also XX% crisis been devices customer the its office enforcement highest In progressed cities the Bureau devices of after adoption handheld between Forces. Recently, of wide Defense changer increase was the chemical to BCI reported prior crisis, of mixture. be Investigation. the has on impact new with enterprise in law the drug May to can customers implemented a in deaths The overdose U.S. program to of pilot really deployed considers substance U.S. to This of to where estimated MXXXX of minutes base and To Enforcement XXX rapid of Administration, The throughout This these testing, one this the opioid there suspected involving agents Homeland MXXXX XX,XXX fentanyl fourth of our overdose the a adoption. depart bringing of The agencies, life has including rates Moving within bag opioids. Office be devices. traction, suspicious Ohio example we an they With and and and police evident a a all In we MXXXX point an to later, Security, in growing General’s agency’s the of Drug XXXX significantly year. overdoses. adoption customers, installed that staggering our mainly leading were XX% from be Department at
includes with and to Training, of objective. best year Our including collectively which and Guardian the for for spec National LSU of organizations, our tactic. goal Centers towards each responders modern become handheld first Research thousands Biomedical making and trading bearer train mass chemical is Georgia the standard global Center response for leading this worldwide are we partnering progress our on This strong
XXXX, placing we the of nearly top these our already have companies November went have company. to the pharmaceutical all purchased Since we sold devices Notably, of and REBEL of now devices XX REBEL desktop XXX top reached desktop, XX of goal XX customers units. have Turning to launch XX multiple into our units. our in pharmaceutical XX% the
product measure quality in CQA control to in a multiple predictability As biotherapeutics. to need we order process or previously and and critical shared, underlying improve monitor the yield there’s to attributes growing and
devices a and year, attributes on with results down papers These are efficiency minutes including GSK published to well desktop XX by researchers gains, process providing conventional control methods. limit Biotechnology Researchers nutrient ZipChip analyte and a growth effective to panel of method Last a to mammalian just paper throughput REBEL was Our Hopkins to simultaneously. quality by needs. use forming LCMS and Amgen minutes, model in measure cost comparable papers processing these facilitate critical power metabolomic byproducts. positioned cells, Johns from of The the XXx to meet in November. University XXX to multiple noted increased developed in published the undesirable demonstrated control Bioengineering
enabling process predictive Our of development The User the model focused was through proteomics. forming REBEL first our modeling Meeting Scientists presented counterfeit at-line REBELs analysis. at work, monitoring, Sartorius on and validation also screening and power in high throughput in and drug by their which silico Integrated demonstrated facilitated device in pharmaceuticals bioprocess
accomplish modules, use extensions, third-party and we of our software the for platform’s the our unlock To software this, panel to year, hardware applications, of integrations. by released and addressable to continued markets. expansion areas increasing customers capabilities during analyte kits, we and accessory new opening platform, technology Moving assay
accessory detect a spec seamless identify transfer hazards, chemical mass aerosol Bluetooth device, handheld our accelerate we released capability an to and data aerosolized module and in the that For field. and enables support
such cannabinoid, We XX drug cathinones and also synthetic opioid. compounds, added mainly as new analyte targets
customers a effective to Recently, their and Sartorius their method ZipChip the our with to harsh integrate with our They Sciences, allow provides illegally substantial device stream partnered agents nucleotide ZipChip to we kits. new kit a data a insights. new them noted analyze of rapid it kit desktops, released types ZipChip workflow SIMCA a For for actionable in our need sample REBEL’s for cost garner small that sample, compared We that they without into all conventional and customers Protein assay CRO requires to deeper of provided something leading the approaches. possibility appreciate within their simple, other European analysis. eye-impairing Protegene, already exploratory tool Oligos only said for the with amount gives new value light
XX scientific largely metabolomics. versus presented ten-fold prototype or microfluidic with showed At and are proteins. desktops, our highlighting at technology as allowing our there bioanalytics Cancer a primary Conference for us microfluidic the including for Annual We chip time of on ASMS, XX Dana-Farber ASMS, savings, using a a lower bioanalytics, which these on our capture their scientists breadth abundance application updated significant the chromatography and traditional we in developments improvement proteomics results opportunity measure Mass beyond the presented is American to Spectrometry focused advances, from community minutes Also products the for While in our chips, methods. of areas. Institute and sensitivity, technologies minutes Society we
opportunity the market our and research and for estimate reaching growing. is in total and our products is pharma, biotech, rapidly addressable Today, across for forensics, large the $X we government approximately bioprocessing, that billion Importantly, products customers academia.
enable and we metrics point our that to of and coming as over nearing emergence shared control real-time industry extend more we in therapies. the the underscore and have with research therapeutics for to $XX need desktop efficiency predictability. bioprocess biopharmaceutical pipeline to capabilities inflection the really industry advanced opportunity We billion desktops and the and to QA/QC is an the our We I handheld that indeed few analytics expand a critical see of grow share for with the want years, this. for the expect increasing process advanced
First, of gene including are for as Alliance X,XXX more trials regenerative of therapies. Medicine ongoing QX that and than cell XXXX, medicine, estimates the there Regenerative clinical
and significant at to gene approximately growing through drug XXXX Conference, Advanced in year XX field experiencing is January, they XX in past XXXX. that new approvals finally, the from original growth FDA FDA this new XXX approximately the expected Suite applications XXX in investigational XXXX. cell therapy stated And approximately to with Therapies advanced per Second, the therapy
therapies to expand total personalized the to the multi-fold traditional batches smaller these of market. antibodies, addressable market these in therapies industry increase trends, over given these Compared we hold nature measurements advanced require the to expect production in Given number our significantly monoclonal the as time a due to continue of therapies. advanced take
growing desktop devices meet for are Our positioned analytics. well this to need
process enables analytes XX attributes monitoring the automates to prediction. productivity and device of the REBEL and critical of streaming cell at-line function Our
quality faster than Our to development. little method rapid characterization ZipChip XXx the simultaneously, with LC new of device enables multiple conventional attributes
We in are significant opportunity device. penetrating this already making REBEL the progress with
placements of in for nearly and from As therapy four applications, every a year double cell year-end, that was ago. REBEL one gene
with and cell and is than confident on partnerships, focused several the more have beginning. therapies research We a this also gene specifically are significant collaborations these of third we only
value proposition industry, as offer strong a continue We have to the to other markets. we believe well as biopharma
are first our our handhelds, laying for trials commercialization; accounts; drive the that to developing areas Starting fifth, opportunities. bioanalytics surrounding we Omics on of forward first, pilots key base installed evolve XXXX, second, strong are Looking focused expanding Foundation valuable utilization address existing adoption, third, we and the foundation and and advancing and accelerating to five with our objective testing, to to within potential long-term fourth, platform; accounts. products; we broadening emerging a customer have our into our increasing enterprise building growth;
of As double of year year-end, X approximately have programs pilot more XX than more XXX now units ago. we than
the units to to XXX-plus units accounts accounts, those and maintained year. significant these ongoing potential We XXX over shipping of XX despite across also accounts enterprise approximately last progressed
We for budget drive see and and customers opportunity with funding pipeline adoption. identify continue enterprise our to to to closely our handhelds work significant
For radiate our a are and employing desktops, penetrate strategy. we
of new biopharma working importantly, we accounts, penetrate We large now foothold. accounts to number radiate across and have are where a the
than sales ago. opportunity at year to is grow, higher a XX% and continues that pipeline of Our end, year
and to commercialization, expand second investments of by are further our XX our to international This investment. position will efforts commercial us and XXXX the Turning to the team geographic continue our we ramping harnessing year. objective, the to end from accelerating plan up
locations our year. deepening of addition the key we our demonstrated regions in have the these the employees build and course of over to upon this progress expect footprint with by We across
efforts the objective, capabilities our product use will platform’s market. the unlock our upon and third expand In well build include further and course utilization the developing of understanding platform. the to we devices areas additional we as a capabilities handheld core, and continuing to this data capability is assay, users. new robust product with as meaningful time, across advance year. Turning organic penetrate analytes technology a to data platform on of reach includes At portfolio differentiated our products, and Furthermore, over REBEL portfolio. active company accessories Today, approximately we advancing of technology to existing customers customers and and growth. our of have to progressively and broad XX% are with leading our for consistent continue releases process the of our increase for for integrations our the addressable the are These over desktop XXXX, pull-throughs driven and our to today at a higher which partners we
on Going forward, months, capitalizing we product cadence products XX capabilities of with every new major months of a of the and releases device anticipate aim cycles. and generations XX expanding on replacement to
fourth our production. are through biotherapeutic development we comprehensive creating platform, broadening bioanalytics bioanalytic to platform objective, our Turning a for
outcomes. and informs the process that of rise in predictive quality, product biomanufacturing broader efficiency and that devices impact demand desire cell’s spec objective, workflows for improvements. critical need abundances, proteins in understand an performance and function, of process industry separation. and are take never solutions and biomanufacturing Biopharma quality The and are Proteomics Omics is X.X greater. an Specialized finally, desired To emerging has in increasingly monitoring scientific measuring automated need the are proteins metabolomics conventional goal attributes are expanding connected within an what cell. spec-based they workflows need product and the a hours the therapies, personnel on our and with better And with and simple, enabler proteomics an opportunities. to where drug become growing been workflow. interest proportion support protein around understanding there to high how to the high and necessitates of and accelerating Our this mass and to present, of product, automated attribute tech production identify are for for The fifth for chromatography. foundation, can achieve workloads cost localization significant is doing process a orchestrate real-time With process in parameters address and with manufacturers we laying sample entire to devices latter, stack they which critical development pipeline. attributes critical bottlenecked Omics analyzer Mass quality determining advanced of With demand, models engineering during their preparation see interest activities analysis drive by and X.X and monitoring product are particular,
to requirements step XXX Thompson, from at in Our a electronically driven just separation with poster just week U.S. and Devices serum minutes. using HUPO be To reduce to accelerate preparation showcasing chip that technology presented the and sensitivity talk has could separations that Conference Dr. completed Charleston, the hours minutes. sample potential end, last Will high-resolution at principal in lightning measurements the scientist attomolar
and We and to publications the product in expect cadence and technology partners continued research domain. support a with of future KOLs launches workflows Omics
have am these throughout We have well execute these confident in XXXX us a tangible I growth we initiatives. XXXX. foundation and are will enable build areas strong and to continued that for a laid on team across positioned results shown we solid
to opportunity and will ahead financials We are democratizing positioned the laboratory will turn bringing need. our who point than and outlook XXXX. call of to on capitalize our towards mass detail to and for the ever our continue goal better I it on discuss now more provide spectrometry the over Joe, of
